Skip to main content
Premium Trial:

Request an Annual Quote

HDC Takes 15 Percent Stake in Smart Personalized Medicine

NEW YORK (GenomeWeb News) – Health Discovery Corp. said today that it has taken a 15 percent equity stake in Smart Personalized Medicine, a prognostic test start-up founded by Richard Caruso, a former HDC board member and chairman and founder of Integra Life Sciences.
 
HDC said last week that Caruso had resigned his position as a board member to negotiate a license to use the firm’s support vector machine technology in developing a breast cancer prognostic test.
 
In addition to the equity stake, HDC will receive a 7.5 percent per-test royalty based on net proceeds from sales of the breast cancer prognostic test, Savannah, Ga.-based HDC said.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.